Articulate Parkinson's Disease-Related Protein E3: Potential Drug Target

Target Name: PTGER3

NCBI ID: G5733

PTGER3

Articulate Parkinson's Disease-Related Protein E3: Potential Drug Target

Parkinson's disease is a common neurodegenerative disease characterized by decreased movement, including muscle rigidity, slow movement, and postural instability. The pathogenesis of Parkinson's disease is not fully understood, but according to research, it is closely related to neuronal damage and abnormal protein metabolism. In recent years, with the rapid development of neuroscience technology, people's research on Parkinson's disease has become more and more in-depth. Today, we are going to introduce a potential Parkinson鈥檚 disease drug target鈥擯arkinson鈥檚 disease-related protein E3 (PTGER3), as well as its importance and research progress.

Parkinson's disease related protein E3

Parkinson's disease-related protein E3 (PTGER3) is a family protein that belongs to a distantly related family of tyrosine kinases CK-4. The levels of Parkinson's disease-related protein E3 in the brains of patients with Parkinson's disease are significantly higher than those in healthy people. In addition, in the brains of Parkinson's disease patients, the Parkinson's disease-related protein E3 is closely related to neuronal damage and abnormal protein metabolism.

The role of Parkinson's disease-related protein E3

The role of Parkinson's disease-related protein E3 in the pathogenesis of Parkinson's disease has been extensively studied. Studies have shown that overexpression of Parkinson's disease-related protein E3 is closely related to the onset of Parkinson's disease. In addition, overexpression of Parkinson's disease-related protein E3 is also closely related to neuronal damage and abnormal protein metabolism.

Detection of Parkinson's disease-related protein E3

The detection of Parkinson's disease-related protein E3 is of great significance for the diagnosis of Parkinson's disease. Currently, researchers have developed a variety of methods to detect Parkinson's disease-related protein E3, including gene knockout, overexpression, and interaction analysis. These methods can not only detect the content of Parkinson's disease-related protein E3, but also reveal its relationship with the onset of Parkinson's disease.

Drug targets for Parkinson's disease-related protein E3

Parkinson's disease-related protein E3, as a new drug target, is of great significance in the treatment of Parkinson's disease. Currently, researchers are exploring the therapeutic effect of Parkinson's disease-related protein E3 as a drug target, and have achieved certain results.

Biological functions of Parkinson's disease-related protein E3

Parkinson's disease-related protein E3 plays an important role in the pathogenesis of Parkinson's disease. Studies have shown that overexpression of Parkinson's disease-related protein E3 is closely related to the onset of Parkinson's disease. In addition, overexpression of Parkinson's disease-related protein E3 is also closely related to neuronal damage and abnormal protein metabolism. These findings provide a certain theoretical basis for the treatment of Parkinson's disease.

Therapeutic value of Parkinson's disease-related protein E3

Parkinson's disease-related protein E3, as a new drug target, is of great significance in the treatment of Parkinson's disease. Currently, researchers are exploring the therapeutic effect of Parkinson's disease-related protein E3 as a drug target, and have achieved certain results. These research results provide new ideas and hope for the treatment of Parkinson's disease.

in conclusion

Parkinson's disease-related protein E3 is a family protein that belongs to a distant family of tyrosine kinases CK-4. In the brains of patients with Parkinson's disease, the content of Parkinson's disease-related protein E3 is significantly higher than that of healthy people, and Parkinson's disease-related protein E3 is closely related to neuronal damage and abnormal protein metabolism. In addition, Parkinson's disease-related protein E3 is also a potential drug target and is of great significance in the treatment of Parkinson's disease. With the continuous development of neuroscience technology, the research on Parkinson's disease-related protein E3 will achieve more results, providing more ideas and hope for the treatment of Parkinson's disease.

Protein Name: Prostaglandin E Receptor 3

Functions: Receptor for prostaglandin E2 (PGE2) (PubMed:8307176, PubMed:7883006, PubMed:8117308, PubMed:8135729, PubMed:7981210). The activity of this receptor can couple to both the inhibition of adenylate cyclase mediated by G(i) proteins, and to an elevation of intracellular calcium (PubMed:7883006, PubMed:8117308, PubMed:8135729, PubMed:7981210). Required for normal development of fever in response to pyrinogens, including IL1B, prostaglandin E2 and bacterial lipopolysaccharide (LPS). Required for normal potentiation of platelet aggregation by prostaglandin E2, and thus plays a role in the regulation of blood coagulation. Required for increased HCO3(-) secretion in the duodenum in response to mucosal acidification, and thereby contributes to the protection of the mucosa against acid-induced ulceration. Not required for normal kidney function, normal urine volume and osmolality (By similarity)

The "PTGER3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTGER3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets